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Background. In experimental models, Type 1 diabetes (T1D) can be prevented by adoptive transfer of CD4+CD25+ (FoxP3+)
suppressor or regulatory T cells. Recent studies have found a suppression defect of CD4+CD25+
high T cells in human disease. In
this study we measure apoptosis of CD4+CD25+
high T cells to see if it could contribute to reduced suppressive activity of these
cells. Methods and Findings. T-cell apoptosis was evaluated in children and adolescent (35 females/40 males) subjects
comprising recent-onset and long-standing T1D subjects and their first-degree relatives, who are at variable risk to develop
T1D. YOPRO1/7AAD and intracellular staining of the active form of caspase 3 were used to evaluate apoptosis. Isolated
CD4+CD25+
high and CD4+CD252 T cells were co-cultured in a suppression assay to assess the function of the former cells. We
found that recent-onset T1D subjects show increased apoptosis of CD4+CD25+
high T cells when compared to both control and
long-standing T1D subjects (p,0.0001 for both groups). Subjects at high risk for developing T1D (2–3Ab+ve) show a similar
trend (p,0.02 and p,0.01, respectively). On the contrary, in long-standing T1D and T2D subjects, CD4+CD25+
high T cell
apoptosis is at the same level as in control subjects (p=NS). Simultaneous intracellular staining of the active form of caspase 3
and FoxP3 confirmed recent-onset FoxP3+ve CD4+CD25+
high T cells committed to apoptosis at a higher percentage (15.362.2)
compared to FoxP3+ve CD4+CD25+
high T cells in control subjects (6.161.7) (p,0.002). Compared to control subjects, both
recent-onset T1D and high at-risk subjects had significantly decreased function of CD4+CD25+
high T cells (p=0.0007 and
p=0.007, respectively). Conclusions. There is a higher level of ongoing apoptosis in CD4+CD25+
high T cells in recent-onset
T1D subjects and in subjects at high risk for the disease. This high level of CD4+CD25+
high T-cell apoptosis could be
a contributing factor to markedly decreased suppressive potential of these cells in recent-onset T1D subjects.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disorder in which
autoreactive T cells attack pancreatic b-cells, leading to a lifelong
dependency on insulin. Twenty years ago, T1D was hypothesized
to be a chronic autoimmune disorder by Eisenbarth[1]. Consider-
able progress has been made in understanding the pathogenesis of
autoimmune disorders since then, but not enough to prevent or
reverse the disease. The abrogation of central and peripheral
tolerance underpins the genesis of all autoimmune diseases[2]. At
the heart of these processes lies apoptosis. In central tolerance,
autoreactive T cells are deleted in the thymus through apoptosis
pathways. Most studies in murine T1D models have found that
autoreactive T cells are resistant to apoptosis[3]. This predisposes
an individual to autoimmune disease as autoreactive T cells find
their way to the periphery and attack the target organ. Only a few
studies have investigated apoptosis of T cells in the periphery in
T1D patients and nearly all before the era of regulatory T cells[4–
6]. There is some evidence that resistance to apoptosis of
autoreactive T cells contributes to human T1D [6]. In parallel,
the thymus produces regulatory T cells whose main action is in the
periphery (control of development, trafficking and proliferation of
responder T cells). Though there are other mechanisms for
peripheral tolerance[7], the role of CD4+CD25+
high T cells with
regulatory function (Tregs) has recently attracted considerable
attention.
Although the existence and function of regulatory T cells is
confirmed in both in vivo and in vitro experiments, exact
identification and isolation has been and continues to be
a problem. The FACS isolation method that gives the high
number of most potent Tregs is based on the highest surface
expression of CD25 (IL2-Ralpha)[8]. These CD4+CD25+
high T
cells are enriched in cells with regulatory properties. It has been
shown in animal models that CD4+CD25+
high T cells can prevent
Academic Editor: Ludvig Sollid, University of Oslo, Norway
Received December 5, 2006; Accepted December 6, 2006; Published January 3,
2007
Copyright:  2007 Glisic-Milosavljevic et al. This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funding: Part of the study was funded through The Max McGee National Center
for Juvenile Diabetes private fund and The Children’s Research Institute. The
study was also funded through GCRC Grant M01-RR00058 from the National
Institutes of Health. The funding source didn’t have any role or influence on study
design, collection of data, analysis and interpretation of results.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: sghosh@mcw.edu
PLoS ONE | www.plosone.org 1 January 2007 | Issue 1 | e146murine T1D[9–11] bringing in new hope for the prevention of
human autoimmune disease. However, CD4+CD25+
high also
include activated (CD4+CD25+) T cells that do not generally
show regulatory properties. Nevertheless, high expression of CD25
on CD4+ cells has been shown to mark a small number of highly
suppressive T cells. Although a specific molecule for regulatory T
cells is lacking, the transcription factor FoxP3 - forkhead box P3,
has been identified as necessary for their development[12]. It has
also been confirmed that cells with regulatory function constitu-
tively express high levels of the FoxP3, but this is an intracellular
transcription factor, so isolation of live human cells based on
FoxP3 staining is not possible. Recently however, some papers
have shown correlation of high expression of FoxP3 and low or no
expression of IL-7R alpha (CD127low/-) on the cell surface[13,14]
Humans without functional FoxP3 protein have an autoimmune
disorder called IPEX with auto-antibodies against a diversity of
organs[15]. However, there are still controversial data about
FoxP3 involvement in regulatory function[16].
Several studies with healthy control subjects and T1D patients
have reported decreased regulatory function of CD4+CD25+
high
T cells in T1D patients[17–20]. Despite accumulating data about
the dysfunction of CD4+CD25+
high T cells in T1D patients, there
is no compelling evidence identifying an underlying cause.
Spontaneous apoptosis of Tregs in human T1D patients as
a mechanism has not been fully investigated.
In this study, we measured apoptosis of CD4+CD25+
high T cells
in relation to their function. Healthy control and several T1D-
related clinical groups were studied. These included recent-onset
T1D subjects and unrelated, unaffected subjects with one, two and
three positive T1D specific auto-antibodies (aAbs) (to GAD, IA-2
and insulin). Those with two or more aAbs are at higher risk for
developing T1D in the future. We also studied longstanding T1D
and T2D patients. Our results implicate a role of increased
apoptosis of CD4+CD25+
high T cells in the pathogenesis of human
T1D. Furthermore, intriguing data presented here shows that
Tregs (FoxP3+ve T cells) within this population contribute most to
the increased apoptosis. However, a strong inverse relationship
between apoptosis of CD4+CD25+
high T cells and their function
needs to be investigated on a larger sample size in different clinical
groups.
METHODS
Seventy-five Wisconsin study subjects (67 Caucasian, 5 Asian, 2
African-American and 1 Hispanic) of both genders (35 females and
40 males) were recruited through the diabetes clinics at Children’s
Hospital of Wisconsin (CHW), Froedtert Hospital (FMLH) and
other local hospitals and clinics that had over 1600 T1D families,
through ascertainment of a proband with the T1D onset before
age of 17. In families with a child proband, siblings and parents
were also asked to join the study. However, just one person from
each family was included in our study. Control subjects were
recruited by posting flyers in areas of the hospitals that might be
visited by potential ‘‘healthy’’ subjects, i.e. orthopedic, dental, and
eye clinics. Inclusion criteria for control subjects were random
blood glucose less then 110 mg/dl, no history of any autoimmune
disorder (including T1D) in the family and an absence of T1D-
specific aAbs. Although healthy subjects of all ages were included
(n=28), age-matched control subjects formed a separate clinical
group (n=10) because of the possible age effect on number and
function of isolated CD4+CD25+high T cells[21]. At-risk subjects
(n=17) were first-degree relatives of T1D patients, but unrelated
to the specific probands included in this study. T1D subjects were
defined according to accepted criteria: high blood glucose levels
($200 mg/dl) with symptoms of diabetes confirmed by a physi-
cian, according to WHO criteria[22]. Recent-onset T1D subjects
(n=14) were recruited after metabolic stabilization and within one
year of diagnosis. Long-standing T1D subjects (n=12) were
diagnosed at least two years earlier. Random glucose levels at the
time of recruitment in this group of subjects were at comparable
levels to the glucose levels measured in recent-onset T1D subjects
(Table 1). Long-standing T2D subjects (n=4) were also diagnosed
at least two years earlier. They were included in the study as
a group with non-autoimmune diabetes. Subjects or their parents
(guardians) provided written informed consent and completed
a questionnaire.
All participants had aAbs and glucose levels measured at the
recruitment visit. An accurate method for the detection of multiple
T1D auto-antibodies developed by Hagopian and collaborators
was employed[23]. His laboratory participated in the 2005 CDC/
IDS Diabetes Autoantibody Standardization Program, with
sensitivity/specificity of 94%/94%, 80%/93% and 76%/93%
for GAD Ab, IA2 Ab and IAA, respectively.
Recent-onset and long-standing T1D and T2D subjects had
HbA1c and insulin dosage recorded at each visit. Peripheral blood
mononuclear cells (PBMC) were collected using vacutainers with
ACD solution B of trisodium citrate and isolation was done using
Ficoll-Hypaque density gradient centrifugation following the
manufacturer’s protocol (Amersham Pharmacia, Uppsala, Swe-
den). Cells were counted and stained with a cocktail of
fluorochrome-conjugated monoclonal antibodies in PBS (APC-
aCD4 (clone RPA-T4), APC-Cy7-aCD25 (clone M-A251), FITC-
aCD14 (clone M5E2), FITC-aCD32 (clone FLI8.26), FITC-
Table 1. Demographic data of subjects involved in the study
..................................................................................................................................................
Demographic Table
Age at Visit
(yr6SE)
Gender
(F/M)
Age at Dx.
(yr6SE)
Duration of
Diabetes
at visit (yr6SE)
Ave units
insulin/kg/day
HbA1c
(%6 SE)
Random
glucose (mg/dl)
Control subjects (n=28) 26.962.6 15/13 89.662.5
Age-matched Control subjects (n=10) 13.665.0 5/5 88.668.6
recent-onset T1D subjects (n=14) 10.861.4 8/6 10.461.4 0.3760.06 0.4960.08 6.9 60.3 205.0620.9
Longstanding T1D subjects (n=12) 16.462.4 3/9 10.661.4 5.461.4 0.7860.07 7.9 60.3 190.3628.0
Low at-risk 1Ab subjects (n=10) 28.865.4 6/4 86.764.6
High at-risk 2Ab subjects (n=4) 26.266.6 1/3 88.867.4
High at-risk 3Ab subjects (n=3) 10.063.5 0/3 89.0619.2
Longstanding T2D subjects (n=4) 38.4611.8 2/2 41.2684 . 6 63.2 5.8 60.3 115.0619.9
doi:10.1371/journal.pone.0000146.t001
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BD Pharmingen, San Diego, CA) and sorted on FACSAria (BD
Biosciences, San Diego, CA). Cells were gated first for live
lymphocyte, eliminating dead cells and debris. Next, two gates
were set up to eliminate non-CD4 T cells (FITC- and PECy7-
conjugated antibodies). CD4+ T cells were further gated as
CD4+CD25- and CD4+CD25+
high using the Fluorochrome
Minus One (FMO) method, that allows a more precise definition
of cells having fluorescence above the background level[24]. The
1% of cells expressing the highest level of CD25 were collected and
defined as CD4+CD25+
high T cells, known to be enriched for
Tregs[25]. These cells showed expected distribution of non-unique
surface markers expected for Tregs (data not shown).
Apoptosis in all samples was measured using our recently
published method [26]. Briefly, cells were stained with YOPRO1
(250 nM) for 20 minutes in the dark and 7AAD (250 ng) was
added 10 minutes before acquiring events. Apoptosis was
measured as the percentage of apoptotic cells (YOPRO1+ve/
7AAD-ve) amongst live cells (total 7AAD-ve cells comprising both
YOPRO1+ve and YOPRO1-ve cells). Using a similar computa-
tion, apoptosis was also measured by intracellular staining of the
active form of caspase 3 (aaCas3), in most cases combined with
intracellular staining of the transcription factor FoxP3, constitu-
tively expressed in the Treg subfraction of CD4+CD25+
high T
cells[27]. Caspase 3 is a key executioner in the apoptosis pathway
and detection of its active form is usually a sign of ongoing
apoptosis. Before we adopted the method of dual staining of FoxP3
and the active form of caspase 3, we confirmed that the results of
single staining for both proteins were similar to results generated
by their simultaneous staining (data not shown).
The only reliable feature of CD4+CD25+
high T cells is their
capacity to suppress proliferation of responder T cells. This
capacity is measured via a proliferation assay, where responder
(CD4+CD252) and suppressor (within the CD4+CD25+
high
population) T cells are stimulated in vitro separately and together
in co-culture under defined conditions. The proliferation assay was
performed using 10,000 responder T cells (CD4+CD252) and
10,000 irradiated PBMCs (5000rad) along with 1,000
CD4+CD25+
high T cells seeded in a 96-well plate. Stimulation
was with aCD3-coated beads (1 ug/ml, 3 beads/cell) for 5 days
under 5% CO2 and saturated humidity. Cells were left in culture
after pulsing (1 mCi of [H
3]-thymidine) for an additional 16 hours,
then harvested and after adding scintillation liquid, read for counts
per minute (cpm). Suppression (%) of Tregs was calculated as
[(cpm of responders in single culture 2 cpm of cells in co-culture)/
cpm of responders in single culture]6100.
The Mann-U-Whitney and Tukey-Kramer tests were used to
compare results between clinical groups with p value #0.05
considered significant. GraphPad software was used for data
presentation. We also performed Kruskal-Wallis in addition to
a one-way ANOVA.
RESULTS
We used a FACS machine for cell separation in this study. The
sorter allows specific isolation of a cell population from
a heterogeneous T-cell mixture, especially if the surface marker
is used as a tag. To minimize the number of activated T cells that
express high levels of CD25, we only collected 1% of cells with the
highest CD25 expression. (CD4+CD25+
high T cells).
In all clinical groups studied, two T-cell subsets (CD4+CD252
and CD4+CD25+
high) were collected and analyzed ex vivo for 1.
proliferation/suppression; 2. apoptosis determination using nucleic
acid stains (YOPRO1/7AAD); 3. intracellular staining for FoxP3
and 4. intracellular staining for aaCas3. The CD4+CD252 T cells
are used as responders in a suppression assay and they also served
as an internal control for the measurement of apoptosis.
Within a uniformly short time after FACS isolation, in all
studied subjects, fresh CD4+CD252 and CD4+CD25+
high T cells
were analyzed for apoptosis using the YOPRO1/7AAD stain
combination[26]. Representative FACS pictures for each group of
patients are presented in Figure 1. CD4+CD25+
high T-cell
apoptosis was significantly different across the clinical groups
(Kruskal-Wallis p,0.0001; ANOVA F=16.07 (df 6, 78),
p,0.0001, Figure 2a). Based on the Tukey-Kramer post-hoc test,
CD4+CD25+
high T-cell apoptosis in recent-onset T1D subjects
differed significantly from all other clinical groups except from the
high at-risk group (Figure 2a). Concurrently, CD4+CD252 T
cells, which were isolated from all subjects at the same visit,
showed no differences in apoptosis levels across the clinical groups
(Kruskal-Wallis p=0.25 NS; ANOVA F=0.73 (df 6, 78), p=0.26;
NS; Figure 2b). Apoptosis of CD4+CD25+
high is the highest in
recent-onset T1D subjects (11.461.1) followed by high at-risk
subjects (8.661.5). The lowest measured CD4+CD25+
high T-cell
apoptosis level is among the longstanding T2D (3.560.4) and is
similar to CD4+CD25+
high T-cell apoptosis among both the
control and longstanding T1D subjects (3.960.5 and 4.060.5
respectively). When compared to control subjects,
CD4+CD25+
high T-cell apoptosis of recent-onset T1D showed
the strongest statistical difference (p,0.0001). We were also able to
recruit ten age-matched control subjects to rule out the possibility
that increased age was associated with reduced apoptosis of
CD4+CD25+
high T cells. Compared to the age-matched control
group, recent-onset T1D subjects showed a significant increase in
CD4+CD25+
high T cell apoptosis (p,0.0001). While not as
noticeable, the high at-risk clinical group (both 2 Ab+ and 3 Ab+)
also showed a significant increase in CD4+CD25+
high T-cell
apoptosis when compared to random control subjects (p=0.008).
In order to confirm our results using YOPRO1/7AAD, we used
a second apoptosis detection method. Thus, an aliquot of isolated
T cells was stained for the presence of active caspase 3. Figure 3a
and 3b present CD4+CD25+
high T-cell apoptosis isolated from the
same subjects measured by two different apoptosis assays. The
apoptosis results were similar. Furthermore, correlation of
apoptosis results measured by these two methods was significant
(Spearman’s rank correlation coefficient r=0.59 (95% CI=0.28–
0.79), p=0.0006). A higher percentage of CD4+CD25+
high T cells
in recent-onset T1D subjects produced more active caspase 3 than
the same T-cell subtype in control subjects, confirming the
ongoing apoptosis detected by YOPRO1/7AAD. Control subjects
had significantly lower apoptosis level from both recent-onset T1D
and high at-risk subjects as measured by intracellular staining of
aaCas3 (p=0.0006 and p=0.009 respectively).
Since CD4+CD25+
high T cells comprise FoxP3+ Tregs[27] as
well as activated T cells, we checked whether cells that were dying
by apoptosis were FoxP3 positive. Simultaneous intracellular
staining of the active form of caspase 3 and FoxP3 confirmed
recent-onset FoxP3+ve CD4+CD25+
high T cells committed to
apoptosis at a higher percentage (15.362.2) compared to
FoxP3+ve CD4+CD25+
high T cells in control subjects (6.161.7;
Figure 4, p,0.002). Of great interest, while FoxP3+ve and FoxP3-
ve CD4+CD25+
high T cells in both control and longstanding T1D
subjects did not show differences in the apoptosis rate, FoxP3+ve
CD4+CD25+
high in recent-onset T1D subjects were significantly
more apoptotic than FoxP3-ve CD4+CD25+
high T cells from the
same individual (Figure 4, p=0.01).
FACS-isolated CD4+CD25+
high T cells were also tested for their
suppressive function using standardized in vitro suppression assays.
Analysis of CD4+CD252/CD4+CD25+
high Tc e l lc o - c u l t u r ea t
Treg Apoptosis in T1D
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high T cells in control
subjects showed average suppression of 46.0.65.9% while high at-
risk and recent-onset T1D subjects showed similar suppression of
10.69.9% and 9.965.5% respectively, Figure 5). Compared to
control subjects, both recent-onset T1D and high at-risk subjects
had significantly decreased function of CD4+CD25+
high Tc e l l s
(p=0.0007 and p=0.007, respectively). Although suppressive
potential of CD4+CD25+
high T cells isolated from longstanding
T1D subjects was higher than in recent-onset T1D subjects, it was
significantly lower when compared to healthy controls (p=0.04).
One must be aware of other factors associated with increased
apoptosis of T cells in the clinical setting. These include ambient
glucose[28] and insulin[29] levels. We provide evidence that these
factors play only a minor role in our apoptosis results. In our
sample, longstanding T1D subjects have similar glucose levels to
recent-onset T1D subjects (p=0.52, NS), similar CD4+CD252 T
Figure 1. Representative FACS pictures of CD4+CD252 and CD4+CD25+
high T cells using YOPRO1/7AAD method from representative subjects of
clinical groups. Apoptosis was calculated as the percentage of apoptotic cells (YOPRO1+ve/7AAD-ve) amongst live cells (total 7AAD-ve cells
comprising both YOPRO1+ve and YOPRO1-ve cells). This is simply designated as YOPRO1+ve.
doi:10.1371/journal.pone.0000146.g001
Treg Apoptosis in T1D
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levels of their fresh CD4+CD25+
high T cells (p,0.0001). Although
exogenous insulin levels are significantly different because of the
honeymoon phase (p=0.004), our data for CD4+CD252 T cells
do not show apoptosis differences, which confirm a non-significant
role of insulin (or any other factor) in the protection from or
genesis of apoptosis. Age-dependent differences in the frequency of
have been shown before[20]. However, in the present study, no
differences in apoptosis of CD4+CD25+
high T cells dependent on
donor age were observed (Mann-Whitney U-test p=0.19).
Figure 2. a) Apoptosis of CD4+CD25+
high T cells in clinical groups measured by YOPRO/7AAD stain combination. CD4+CD25+
high T cells in recent-
onset and in high at-risk subjects for developing T1D show significantly higher apoptosis levels: Kruskal-Wallis p,0.0001; ANOVA F=16.07 (df 6, 78)
p,0.0001. Specifically, Control vs. recent-onset T1D p,0.0001; age-matched control vs. recent-onset p,0.0001; recent-onset T1D vs. long-standing
T1D p,0.0001; recent-onset T1D vs. low at-risk p,0.0001; control vs. high at-risk p,0.008; high at-risk vs. long-standing T1D p=0.01).
b) Apoptosis of CD4+CD252 T cells measured by YOPRO/7AAD stain combination across studied clinical groups (Kruskal-Wallis p=0.25; ANOVA
F=0.59, df (6, 78), NS). Apoptotic cells are presented on y-axis as YOPRO1+ve.
doi:10.1371/journal.pone.0000146.g002
Figure 3. Comparison of apoptosis measurement in the same subjects using two different methods.
a) CD4+CD25+
high T cells apoptosis in three clinical groups using YOPRO/7AAD stain combination; control subjects CD4+CD25+
high T cells apoptosis
significantly differs from both recent-onset T1D and high at-risk subjects (p=0.0001 and p=0.01, respectively). Apoptotic cells are presented on y-
axis as YOPRO1+ve.
b) CD4+CD25+
high T cells apoptosis in the same subjects using intracellular staining of aaCas3. CD4+CD25+
high T cells apoptosis from control subjects
significantly differs from both recent-onset T1D and high at-risk subjects (p=0.0006 and p=0.009, respectively). Spearman’s rank correlation
coefficient between two apoptosis measurement methods in control and recent-onset T1D subjects is significant (r=0.59 and p=0.0006). Apoptotic
cells are presented on y-axis as aaCas3+ve.
doi:10.1371/journal.pone.0000146.g003
Treg Apoptosis in T1D
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In this study, we aimed to measure apoptosis and function of
CD4+CD25+
high T cells in T1D families and control subjects.
Although a recent study shows that 2–3% of the highest CD25-
expressing T cells can be safely sorted as Tregs[30], we only collect
the top 1%. This is because subjects with ongoing autoimmune
disease have more activated T cells that also express CD25, even
though these cells possess no regulatory properties. For now, the
presence of true Tregs is best defined by their functional activity,
which in vitro, is monitored by suppression of the proliferation of
responder T cells. In fact, recent studies in vivo have confirmed that
Tregs probably act in a similar manner by inhibiting the interaction
between antigen-presenting cells and responder T cells, leading to
reduced proliferation of the latter cells[31]. Most groups have
reported regulatory T-cell (CD4+CD25+
high) dysfunction in T1D
[17,20]. None have found a cause for this dysfunction.
We present evidence that increased apoptosis of Tregs could
potentially play a role in the pathogenesis of human T1D, a major
autoimmune disease. Apoptosis was measured in freshly isolated
CD4+CD25+
high T cells from T1D families and control subjects.
The highest levels of apoptosis were found in recent-onset T1D
subjects and in individuals at high risk (2+3Ab+ve) for disease
(Figure 2). This important observation was only possible after we
developed a novel, sensitive stain combination (YOPRO1/7-AAD)
for the detection of early apoptosis [26]. YOPRO1 is a small
molecule that enters the apoptotic cells readily compared to other
stains.
Our data suggest that individuals who are positive for one Ab
(low risk to develop T1D) have a low apoptosis level of
CD4+CD25+
high T cells that is similar to control subjects. The
percentage of apoptosis increases with the number of Abs detected
in the serum, reaching the highest level in subjects at the onset of
the disease staying high during the period immediately following
diagnosis. It is during this period that requirements for exogenous
insulin drop dramatically and beta cell function improves
(‘‘honeymoon’’ phase). Later on, when the autoimmune de-
struction is complete and insulin requirements increase,
CD4+CD25+
high T-cell apoptosis goes back to the level detected
in healthy control subjects.
Our results with the new stain combination are confirmed with
a second, independent, apoptosis detection method on the same
samples. The second method was the intracellular staining for the
active form of caspase 3. Generated results parallel the apoptosis
data in the CD4+CD25+
high T-cell fraction using YOPRO1/7-
AAD (Figure 3). These results also suggest that apoptosis in recent-
onset T1D subjects involves pathways with caspase 3. Further-
more, with the simultaneous staining for the active form of caspase
3 and the transcription factor FoxP3, we are able to differentiate
apoptosis based on FoxP3 expression in CD4+CD25+
high T cells
(Figure 4). These results suggest that it is the true Tregs
(FoxP3+CD4+CD25+
high T cells) that contribute most to the
apoptosis seen in highest CD25-expressing T cells.
Even though under intense investigation during the last several
years, it has not been completely determined why CD4+CD25+
high
TcellshavereducedinvitrosuppressivecapacityinT1D.Someofthe
possible causes include insufficient amount of ambient IL2[32],
mutations in FoxP3[33] prevention of CD4+CD25+
high Tc e l l s
development or non-functional TGF-bR on the surface of responder
T cells [34]. The only report that we are aware of shows increased
apoptosis of human CD4+CD25+
high Tc e l l sa f t e rF A C Si s o l a t i o n
but under specific conditions (Fritzsching et al., 2005) [35]. No
reports have yet appeared to link increased apoptosis in the
unmanipulated CD4+CD25+
high T-cell fraction with respect to
autoimmune disease.
Figure 4. CD4+CD25+
high T cells apoptosis levels within FoxP3+ve and
FoxP3-ve cell subpopulation across three clinical groups. FoxP3+ve
CD4+CD25+
high T cells show significantly higher apoptosis level
(intracellular staining of aaCas3) compared to FoxP3-ve CD4+CD25+
high
T cells in recent-onset T1D only (Kruskal-Wallis, p=0.0066); recent-onset
T1D CD4+CD25+
high T cells FoxP3+ve vs. FoxP3-ve p=0.01; FoxP3+ve
CD4+CD25+
high T cells control vs. FoxP3+ve CD4+CD25+
high T cells
recent-onset T1D p,0.002. FoxP3-ve CD4+CD25+
high T cells control vs.
FoxP3-ve CD4+CD25+
high T cells recent-onset T1D p=0.01. Apoptotic
cells are presented on y-axis as aaCas3+ve.
doi:10.1371/journal.pone.0000146.g004
Figure 5. CD4+CD25+
high T cells suppressive potential across major
clinical groups. Control subjects show statistically higher suppression
compared to the other three groups recent-onset T1D, high at-risk and
longstanding T1D subjects (p=0.0007, p=0.007 and p=0.04, re-
spectively). Standardized suppression assay was performed with
1610
4 responder T cells, 10
4 irradiated PBMCs (5000rad) alone and in
co-culture with CD4+CD25+
high T cells in 1:10 ratio, stimulated with
aCD3 coated beads (1ug/ml, 3 beads/per cell).
doi:10.1371/journal.pone.0000146.g005
Treg Apoptosis in T1D
PLoS ONE | www.plosone.org 6 January 2007 | Issue 1 | e146How does increased apoptosis of Tregs affect their function?
Since in vitro suppression is the only functional test, we have
developed a robust assay (Jana et al, in preparation). High
suppression in control subjects using our high co-culture ratio
ensures that functionally these are true suppressor cells. Significant
suppression differences between control and recent-onset T1D
subjects following the same experimental conditions, point to
a functional impairment of regulatory cells seen in the recent-onset
T1D clinical group (Figure 5). This result is in agreement with
previous studies done with recent-onset T1D patients[17].
Another comprehensive study also reported T1D patients having
deficient function of CD4+CD25+
high T cells[20].
The novel stain combination for apoptosis measurement used
here for the first time in a study involving diabetic patients
correlates well with the number of diabetes-specific auto-
antibodies. A future longitudinal study on more subjects will give
direct proof that ongoing apoptosis of CD4+CD25+
high T cells
leads to reduced suppression and the beginning of T1D. Although
other tests for the prediction of T1D exist (family history and HLA
genotyping), we believe that this easy-to-use method that captures
early apoptosis of CD4+CD25+
high T cells may be of value as
a marker for individuals at T1D risk and that it opens up a new
area in T1D investigation.
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